HC Wainwright Lowers Earnings Estimates for Editas Medicine

Editas Medicine, Inc. (NASDAQ:EDIT) – Equities research analysts at HC Wainwright decreased their FY2025 EPS estimates for Editas Medicine in a research report issued on Monday, November 24th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($1.45) per share for the year, down from their prior estimate of ($1.43). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Editas Medicine’s Q4 2025 earnings at ($0.17) EPS, Q1 2026 earnings at ($0.33) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($1.16) EPS.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.10. The company had revenue of $7.54 million during the quarter, compared to analyst estimates of $4.95 million. Editas Medicine had a negative net margin of 430.84% and a negative return on equity of 277.29%.

EDIT has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Editas Medicine in a research report on Wednesday, October 8th. Chardan Capital raised shares of Editas Medicine from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 13th. Wall Street Zen raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Friday, September 26th. Robert W. Baird raised their price objective on shares of Editas Medicine from $4.00 to $6.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 13th. Finally, Wells Fargo & Company boosted their price objective on Editas Medicine from $3.00 to $4.00 and gave the stock an “equal weight” rating in a report on Wednesday, September 3rd. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.29.

Editas Medicine Trading Up 0.4%

NASDAQ EDIT opened at $2.40 on Wednesday. The firm has a market capitalization of $234.29 million, a P/E ratio of -1.01 and a beta of 2.23. The firm’s fifty day moving average price is $3.20 and its two-hundred day moving average price is $2.67. Editas Medicine has a 1 year low of $0.91 and a 1 year high of $4.54.

Hedge Funds Weigh In On Editas Medicine

A number of hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC increased its stake in Editas Medicine by 13.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 51,105 shares of the company’s stock valued at $112,000 after acquiring an additional 6,088 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Editas Medicine by 33.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 27,168 shares of the company’s stock worth $94,000 after purchasing an additional 6,787 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Editas Medicine during the 3rd quarter valued at about $36,000. Captrust Financial Advisors purchased a new position in shares of Editas Medicine during the 2nd quarter valued at about $26,000. Finally, Sei Investments Co. bought a new stake in Editas Medicine in the 3rd quarter worth approximately $46,000. Institutional investors and hedge funds own 71.90% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.